Lineage Cell Therapeutics (LCTX) Gross Margin (2011 - 2026)

Lineage Cell Therapeutics has reported Gross Margin for 16 years, with the latest figure at 100.0% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin rose 240.0% year-over-year to 100.0%; the trailing twelve-month figure through Mar 2026 stood at 99.26% (up 210.0% YoY), and the FY2025 full-year result was 99.0%, up 251.0% from the prior year.
• Gross Margin for Q1 2026 stood at 100.0%, up from 99.0% in the prior quarter.
• The five-year high for Gross Margin was 100.0% in Q1 2026, with the low at 86.44% in Q3 2023.
• Historically, Gross Margin has averaged 95.46% across 5 years, with a median of 96.06% in 2023.
• Annual changes were most pronounced in 2022 — Gross Margin soared 9275 bps — and 2023, when it plunged 693 bps.
• Lineage Cell Therapeutics' Gross Margin stood at 94.67% in 2022, then declined by 7 bps to 87.74% in 2023, then climbed by 8 bps to 94.63% in 2024, then grew by 5 bps to 99.0% in 2025, then advanced by 1 bps to 100.0% in 2026.
• The last three Gross Margin figures came in at 100.0% (Q1 2026), 99.0% (Q4 2025), and 99.86% (Q3 2025), per Business Quant data.